Network-Based and Machine-Learning Approaches Identify Diagnostic and Prognostic Models for EMT-Type Gastric Tumors

Genes (Basel). 2023 Mar 19;14(3):750. doi: 10.3390/genes14030750.

Abstract

The microsatellite stable/epithelial-mesenchymal transition (MSS/EMT) subtype of gastric cancer represents a highly aggressive class of tumors associated with low rates of survival and considerably high probabilities of recurrence. In the era of precision medicine, the accurate and prompt diagnosis of tumors of this subtype is of vital importance. In this study, we used Weighted Gene Co-expression Network Analysis (WGCNA) to identify a differentially expressed co-expression module of mRNAs in EMT-type gastric tumors. Using network analysis and linear discriminant analysis, we identified mRNA motifs and microRNA-based models with strong prognostic and diagnostic relevance: three models comprised of (i) the microRNAs miR-199a-5p and miR-141-3p, (ii) EVC/EVC2/GLI3, and (iii) PDE2A/GUCY1A1/GUCY1B1 gene expression profiles distinguish EMT-type tumors from other gastric tumors with high accuracy (Area Under the Receiver Operating Characteristic Curve (AUC) = 0.995, AUC = 0.9742, and AUC = 0.9717; respectively). Additionally, the DMD/ITGA1/CAV1 motif was identified as the top motif with consistent relevance to prognosis (hazard ratio > 3). Molecular functions of the members of the identified models highlight the central roles of MAPK, Hh, and cGMP/cAMP signaling in the pathology of the EMT subtype of gastric cancer and underscore their potential utility in precision therapeutic approaches.

Keywords: EMT subtype; WGCNA; epithelial-mesenchymal transition; gastric cancer; machine learning; microRNA; motif analysis; precision medicine.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Cell Line, Tumor
  • Gene Expression Profiling
  • Humans
  • MicroRNAs* / genetics
  • MicroRNAs* / metabolism
  • Prognosis
  • Stomach Neoplasms* / diagnosis
  • Stomach Neoplasms* / genetics
  • Stomach Neoplasms* / metabolism

Substances

  • MicroRNAs

Grants and funding

We acknowledge the Vice Chancellor for Research and Technology of the Semnan University. The authors also would like to thank the Iran National Science Foundation (INSF) for funding this work, through grant number 96006436. U.S. received support from the National Health and Medical Research Council (Investigator Grant 1196405) and the Cancer Council NSW (project grant RG20-12).